Skip to main content

Table 2 Prevalence of Contraindications to Combined Hormonal Contraceptives

From: Factors associated with contraceptive use among women living with HIV in Canada: a controlled, cross-sectional study

Type of Contraindication Controls
(n = 62)
WLWH
(n = 83)
p-value
Medical Contraindication@, n (%) 6 (10%) 14 (17%) 0.14
Current Tobacco Smoker ≥ 35y, n (%) 4(6%) 25 (30%) 0.0008
Drug Contraindication*, n (%) 0 (0%) 21 (25%) 0.0001
 ≥ 1 Contraindication to CHC, n (%) 8 (13%) 45 (54%) 0.0001
  1. Bolded characters represent statistically significant values
  2. Women living with HIV (WLWH), Combined Hormonal Contraceptive (CHC)
  3. @Medical Contraindication: Hypertension, deep vein thrombosis/pulmonary embolism, diabetes with retinopathy, neuropathy, or nephropathy, diabetes > 20 years, migraine with aura, liver tumour, heart attack/myocardial infarction, stroke, severe cirrhosis, active cancer or any history of breast cancer
  4. *Drug Contraindication: Current use of rifampicin, rifabutin, phenytoin, carbamazepine, topiramate, phenobarbital, oxcarbazepine, primidone, lamotrigine, efavirenz, darunavir, or combined use of ritonavir/lopinavir